{"type":"trials","record":{"id":41929,"source_id":"clinicaltrials-gov","external_id":"NCT04005352","title":"Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)","brief_summary":"This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":734,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Israel","Italy","Malaysia","Netherlands","Portugal","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"start_date":"2019-09-25","completion_date":"2022-09-09","last_update_date":"2024-10-09","source_url":"https://clinicaltrials.gov/study/NCT04005352","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"TALON","age_range":"50 Years","comparator":"Aflibercept 2 mg","organization":"Novartis","interventions":["Brolucizumab 6 mg","Aflibercept 2 mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye — Up to Week 32","Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA) - Study Eye — Baseline, Week…","Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye — Up to Week 64","Distribution of the Maximal Intervals With no Disease Activity up to Week 64 - Study Eye — Up to Week 64","Number of Participants With no Disease Activity - Study Eye — Weeks 14 and 16","Time From Last Loading Injection to First Visit With No Disease Activity (Weeks) - 75th Percentile - Study Eye — Up to…","Time-to-first Dry Retina - Time to the First Visit With no Intraretinal Fluid (IRF) or Subretinal Fluid (SRF) - Study E…","Average Change From Baseline at Week 60 and Week 64 in Best-corrected Visual Acuity (BCVA) - Study Eye — Baseline, Week…","Number of Participants With Best-corrected Visual Acuity Improvements of ≥ 15 Letters in BCVA From Baseline or Reached…","Number of Participants With Best-corrected Visual Acuity ≥ 69 Letters - Study Eye — Week 32 and Week 64","Average Change From Baseline in Central Subfield Thickness (CSFT) - Study Eye — Baseline, Weeks 28 and 32 and at Weeks…","Number of Participants With Presence of Intraretinal Fluid and/or Subretinal Fluid in the Central Subfield - Study Eye…","Number of Participants With Presence of Sub-Retinal Pigment Epithelium Fluid in the Central Subfield - Study Eye — At W…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Composite Scores - Study Eye — Baseline, Week 32,…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - General Vision - Study Eye — Base…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Ocular Pain - Study Eye — Baselin…","Change From Baseline n Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Near Activities - Study Eye — Base…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Distance Activities - Study Eye —…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Social Functioning - Study Eye —…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Mental Health - Study Eye — Basel…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":true},"controlled_terms":["Age-related Macular Degeneration","Brolucizumab 6 mg","Aflibercept 2 mg"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04005352","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-09-25 to 2022-09-09","comparator":"Aflibercept 2 mg","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.894Z","intervention":["Brolucizumab 6 mg","Aflibercept 2 mg"],"participants":734,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye — Up to Week 32","Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA) - Study Eye — Baseline, Week…","Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye — Up to Week 64","Distribution of the Maximal Intervals With no Disease Activity up to Week 64 - Study Eye — Up to Week 64","Number of Participants With no Disease Activity - Study Eye — Weeks 14 and 16","Time From Last Loading Injection to First Visit With No Disease Activity (Weeks) - 75th Percentile - Study Eye — Up to…","Time-to-first Dry Retina - Time to the First Visit With no Intraretinal Fluid (IRF) or Subretinal Fluid (SRF) - Study E…","Average Change From Baseline at Week 60 and Week 64 in Best-corrected Visual Acuity (BCVA) - Study Eye — Baseline, Week…","Number of Participants With Best-corrected Visual Acuity Improvements of ≥ 15 Letters in BCVA From Baseline or Reached…","Number of Participants With Best-corrected Visual Acuity ≥ 69 Letters - Study Eye — Week 32 and Week 64","Average Change From Baseline in Central Subfield Thickness (CSFT) - Study Eye — Baseline, Weeks 28 and 32 and at Weeks…","Number of Participants With Presence of Intraretinal Fluid and/or Subretinal Fluid in the Central Subfield - Study Eye…","Number of Participants With Presence of Sub-Retinal Pigment Epithelium Fluid in the Central Subfield - Study Eye — At W…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Composite Scores - Study Eye — Baseline, Week 32,…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - General Vision - Study Eye — Base…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Ocular Pain - Study Eye — Baselin…","Change From Baseline n Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Near Activities - Study Eye — Base…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Distance Activities - Study Eye —…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Social Functioning - Study Eye —…","Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Mental Health - Study Eye — Basel…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41929","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}